Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries

10+ emerging markets, Japan & ANZ transition in final phase

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations

Biocon appoints Karthik SM as Head HR for India, Malaysia and Emerging Markets

In his new role, Karthik will lead human capital strategy and HR operations across these regions

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore

Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar

Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized

Amgen confident in US biosimilar market’s strength as sales surge 52%

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore